<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>DSpace Collection:</title>
    <link>http://localhost:80/xmlui/handle/123456789/14442</link>
    <description />
    <pubDate>Fri, 24 Apr 2026 13:32:24 GMT</pubDate>
    <dc:date>2026-04-24T13:32:24Z</dc:date>
    <item>
      <title>Optimization of process variables for increased production of lovastatin in Aspergillus terreus PU-PCSIR1 and its characterization</title>
      <link>http://localhost:80/xmlui/handle/123456789/15019</link>
      <description>Title: Optimization of process variables for increased production of lovastatin in Aspergillus terreus PU-PCSIR1 and its characterization
Authors: Hassan, Abida; Saleem, Yasar; Chaudhry, Muhammad Nawaz; Asghar, Amina; Saleem, Muhammad; Nawaz, Shaista; Syed, Quratulain; Iqbal, Muhammad Shaheen; Shahzad, Khurram
Abstract: During intrinsic cholesterol formation 3-hydroxy-3-methylgutaryl coenzyme A reductase (HMGCR) converts&#xD;
HMGCoA to mevalonate, in biosynthetic cascade of cholesterol. Statins, competitive inhibitors of HMGCR, now-a-days commonly used to lower the blood-cholesterol level in the hyper-cholesterolemic patients. Lovastatin, one of the most potent natural statins, was produced from wild-type indigenous isolate Aspergillus terreus PU-PCSIR-1, through solid state fermentation (SSF). This study was carried out to investigate different parameters influencing lovastatin production such as pH, carbon source, nitrogen source and media components etc. Each parameter was investigated separately to optimize lovastatin production. Maximum yield of 2860mg/Kg of total lovastatin, comprising 1700 and 1160mg/Kg of hydroxy and lactone forms respectively, was achieved after incubating for 14 days, pH 5.5 and at 28°C. The integrity of biotechnologically-produced lovastatin was analyzed using high performance liquid chromatography (HPLC). Lovastatin was purified by preparative HPLC, and was characterized by FT-IR and LC-MS analyses. The study revealed that A. terreus PU-PCSIR-1 has been proved to be a potent strain for the production of lovastatin that has great pharmaceutical and commercial applications.</description>
      <pubDate>Fri, 18 Jan 2019 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://localhost:80/xmlui/handle/123456789/15019</guid>
      <dc:date>2019-01-18T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Enhancement of solubility and dissolution profile of artesunate by employing solid dispersion approach: An in-vitro evaluation</title>
      <link>http://localhost:80/xmlui/handle/123456789/15016</link>
      <description>Title: Enhancement of solubility and dissolution profile of artesunate by employing solid dispersion approach: An in-vitro evaluation
Authors: Saeed, Muhammad Asad; Ansari, Muhammad Tayyab; Ch, Bashir Ahmad
Abstract: Current study was designed with an aim to improve the solubility and dissolution profile of artesunate by&#xD;
preparing solid dispersions through solvent evaporation and freeze-drying techniques using polyethylene glycol 4000 (PEG4000) as solubility enhancer. Developed formulations were characterized for FTIR, XRD, TGA and SEM. Maximum increase in solubility was attained by freeze-dried solid dispersions (FD F444) i.e. 2.99 folds and 2.66 folds by solvent evaporation solid dispersion (SE F44) as compare to pure drug. Amorphous nature of artesunate in solid dispersions was confirmed from XRD diffractographs. Surface morphology indicated the existence of rough surface in freeze- dried solid dispersions (FDDs) and smooth surface in solvent evaporation solid dispersions (SEDs). Rapid dissolution rates were exhibited by fast dissolving tablets of optimized formulations. Moreover, the release of the drug was dominated by the first order kinetics (R2 = 0.9932) with the Fickian type of diffusion mechanism (n&lt;0.450).</description>
      <pubDate>Thu, 17 Jan 2019 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://localhost:80/xmlui/handle/123456789/15016</guid>
      <dc:date>2019-01-17T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Study on structural insight of the analysis of negative effects of opioids analgesics in naltrexone with TLR4 Mutations</title>
      <link>http://localhost:80/xmlui/handle/123456789/15014</link>
      <description>Title: Study on structural insight of the analysis of negative effects of opioids analgesics in naltrexone with TLR4 Mutations
Authors: Tariq, Iqra; Farhan, Ali; Ashfaq, Usman Ali; Qasim, Muhammad; Rehman, Mahmood-ur; Humayun, Fahad; Shah, Masaoud; Munir, Anum; Masoud, Muhammad Shareef
Abstract: Chronic pain has been defined as the persistence that remained for more than three months. The extent of&#xD;
previous time duration with the normal time of natural healing phase becomes poor and results in reduced life quality and morbidity. Opioids are well recognized therapy for pain management and the clinical prescriptions based on opioids have been defined with increasing implicating behavior among patients suffering with chronic pain. The association between the pain and immunity has long been established since the involvement of interleukin-1ß (IL-1ß) in sickness that is considered with the induced hyperalgesia. In the context of pharmacodynamics Toll like receptors (TLRs) are involved in the negative effects of opioids as analgesics. The soluble factors released by immune cells as well as from the disruptive cells bind to TLRs. This binding leads the pre and post-synaptic ends on endothelial and microglial cells that exhibit the activation of complex inhibitory and excitatory process at the synapses site. In TLRs, TLR4 is mostly reported that is strongly associated in specifically in areas of T cells and macrophages. The current study is designed to investigate the structural insights of the opioids and TLR4 interactions by using computational approach in the aspect of&#xD;
recognizing the chemical combinatorial factors that are involved in the pain management. This study targets that how opioids interact with TLR4 and the process of chemical interaction that leads to negative effects of opioids at neuroimmune interface as well as to investigate the extent of particular naltrexone that mediates with the negative effects of opioids.</description>
      <pubDate>Wed, 16 Jan 2019 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://localhost:80/xmlui/handle/123456789/15014</guid>
      <dc:date>2019-01-16T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Chewable cough tablets with improved palatability: A comparative phase II clinical trial</title>
      <link>http://localhost:80/xmlui/handle/123456789/15011</link>
      <description>Title: Chewable cough tablets with improved palatability: A comparative phase II clinical trial
Authors: Khan, Mehwish; Rehman, Hina; Naveed, Safila; Zaidi, Syed Faisal; Ayaz, Sultan; Owais, Aymen; Usmanghani, Khan
Abstract: Cough is the common disease condition which affects patients of every age. Numerous OTC medications&#xD;
available in community pharmacies however no antiviral treatment and even antibiotics has been shown to be effective without pre-existing lung infection. The treatment approach of medicinal herbs has been recognized for many decades and even longer for the treatment and prevention of cough. The aim of this study was to evaluate the safety and efficacy of Mukalbion poly herbal chewable tablets for the treatment of cough with improved palatability against a marketed brand (Poly herbal). For the formulation development of test group, the herbs were supplied by the Procurement department of Herbion Pakistan Pvt. Ltd. Althea officinalis (roots), Hedera helix (leaves) and Sisymbrium irio (seeds) were used for the manufacturing of Mukalbion (poly herbal, test group) chewable tablet. The comparative control clinical trial was carried out during a time frame of 07 months with sample size of 70 patients as per epidemiological software for sample size and each group contained 35 (±5) patients. Chewable tablets were administered and evaluated for effectiveness after 15 days of treatment. The data were collected by the patients through clinical trial questionnaire. The validated quality of life questionnaire (LCQ) was also used for assessment. The results were analyzed by applying paired sample T test by using IBM SPSS version 20.00. The p value was ≤0.005 at 95% confidence interval for cough&#xD;
variables including cough bouts, viscosity of sputum, chest congestion, sore throat and shortness of breath. The LCQ cough scale score was higher in test group as compared to control group. The test group also showed well tolerated in term of palatability. None of the patient claimed any of the side effects and no compliance were observed against the marketed brand.</description>
      <pubDate>Tue, 15 Jan 2019 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://localhost:80/xmlui/handle/123456789/15011</guid>
      <dc:date>2019-01-15T00:00:00Z</dc:date>
    </item>
  </channel>
</rss>

